Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder

Expert Review of Neurotherapeutics

Volumn 12, Issue 8, 2012, Pages 993-1009

  Dalrymple, Kristy L ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

cognitive behavior therapy; comorbidity; diagnosis; etiology; pharmacotherapy; social phobia; treatment

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; CLONAZEPAM; CYCLOSERINE; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

COGNITIVE THERAPY; COMORBIDITY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DSM-5; DSM-IV; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NEUROIMAGING; NONHUMAN; PSYCHOTHERAPY; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SOCIAL INTERACTION; SOCIAL PHOBIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; INTERPERSONAL RELATIONS; PHOBIC DISORDERS;

EID: 84866685578     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.81     Document Type: Review

References (152)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision. American Psychiatric Association, DC, USA (2000).
2. Furmark T. Social phobia: overview of community surveys. Acta Psychiatr. Scand. 105(2), 84-93 (2002).
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 593-602 (2005).
4. Dalrymple KL, Zimmerman M. Screening for social fears and social anxiety disorder in psychiatric outpatients. Compr. Psychiatry 49(4), 399-406 (2008).
5. Beesdo K, Bittner A, Pine DS et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch. Gen. Psychiatry 64(8), 903-912 (2007).
6. Vriends N, Becker ES, Meyer A, Williams SL, Lutz R, Margraf J. Recovery from social phobia in the community and its predictors: data from a longitudinal epidemiological study. J. Anxiety Disord. 21(3), 320-337 (2007).
7. Yonkers KA, Dyck IR, Keller MB. An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. Psychiatr. Serv. 52(5), 637-643 (2001).
8. Grant BF, Hasin DS, Blanco C et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66(11), 1351-1361 (2005).
9. Acarturk C, de Graaf R, van Straten A, Have MT, Cuijpers P. Social phobia and number of social fears, and their association with comorbidity, health-related quality of life and help seeking: a population-based study. Soc. Psychiatry Psychiatr. Epidemiol. 43(4), 273-279 (2008).
10. Heimberg RG, Becker RE. Cognitive-Behavioral Group Therapy for Social Phobia: Basic Mechanisms and Clinical Strategies. Guilford Press, NY, USA (2002).
11. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am. J. Psychiatry 155(5), 613-619 (1998).
12. Katzelnick DJ, Kobak KA, DeLeire T et al. Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry 158(12), 1999-2007 (2001).
13. Wittchen HU, Fuetsch M, Sonntag H, Mller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study. Eur. Psychiatry 15(1), 46-58 (2000).
14. Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am. J. Psychiatry 157(10), 1606-1613 (2000).
15. Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P. Economic costs of social phobia: a population-based study. J. Affect. Disord. 115(3), 421-429 (2009).
16. Cuthbert BN. Social anxiety disorder: trends and translational research. Biol. Psychiatry 51(1), 4-10 (2002).
17. Stein DJ, Phillips KA, Bolton D, Fulford KW, Sadler JZ, Kendler KS. What is a mental/psychiatric disorder? From DSM-IV to DSM-V. Psychol. Med. 40(11), 1759-1765 (2010).
18. Birbaumer N, Grodd W, Diedrich O et al. fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 9(6), 1223-1226 (1998).
19. Schneider F, Weiss U, Kessler C et al. Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol. Psychiatry 45(7), 863-871 (1999).
20. Tillfors M, Furmark T, Marteinsdottir I et al. Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am. J. Psychiatry 158(8), 1220-1226 (2001).
21. Freitas-Ferrari MC, Hallak JE, Trzesniak C et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(4), 565-580 (2010).
22. Evans KC, Wright CI, Wedig MM, Gold AL, Pollack MH, Rauch SL. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress. Anxiety 25(6), 496-505 (2008).
23. Shah SG, Klumpp H, Angstadt M, Nathan PJ, Phan KL. Amygdala and insula response to emotional images in patients with generalized social anxiety disorder. J. Psychiatry Neurosci. 34(4), 296-302 (2009).
24. Lorberbaum JP, Kose S, Johnson MR et al. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 15(18), 2701-2705 (2004).
25. Furmark T, Henningsson S, Appel L et al. Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J. Psychiatry Neurosci. 34(1), 30-40 (2009).
26. Furmark T, Appel L, Henningsson S et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J. Neurosci. 28(49), 13066-13074 (2008).
27. Sareen J, Campbell DW, Leslie WD et al. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol. Psychiatry 61(3), 396-404 (2007).
28. Blair K, Shaywitz J, Smith BW et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am. J. Psychiatry 165(9), 1193-1202 (2008).
29. Condren RM, ONeill A, Ryan MC, Barrett P, Thakore JH. HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology 27(6), 693-703 (2002).
30. Nater UM, La Marca R, Florin L et al. Stress-induced changes in human salivary alpha-amylase activity -associations with adrenergic activity. Psychoneuroendocrinology 31(1), 49-58 (2006).
31. Martel FL, Hayward C, Lyons DM, Sanborn K, Varady S, Schatzberg AF. Salivary cortisol levels in socially phobic adolescent girls. Depress. Anxiety 10(1), 25-27 (1999).
32. Gerlach AL, Wilhelm FH, Roth WT. Embarrassment and social phobia: the role of parasympathetic activation. J. Anxiety Disord. 17(2), 197-210 (2003).
33. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am. J. Psychiatry 157(3), 457-459 (2000).
34. Warwick JM, Carey P, Van der Linden G et al. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab. Brain Dis. 21(2-3), 241-252 (2006).
35. Tiihonen J, Kuikka J, Bergstrm K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am. J. Psychiatry 154(2), 239-242 (1997).
36. Furmark T, Tillfors M, Garpenstrand H et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci. Lett. 362(3), 189-192 (2004).
37. Stein MB, Chartier MJ, Kozak MV, King N, Kennedy JL. Genetic linkage to the serotonin transporter protein and 5HT2A receptor genes excluded in generalized social phobia. Psychiatry Res. 81(3), 283-291 (1998).
38. Knappe S, Lieb R, Beesdo K et al. The role of parental psychopathology and family environment for social phobia in the first three decades of life. Depress. Anxiety 26(4), 363-370 (2009).
39. Kendler KS, Myers J, Prescott CA, Neale MC. The genetic epidemiology of irrational fears and phobias in men. Arch. Gen. Psychiatry 58(3), 257-265 (2001).
40. Distel MA, Vink JM, Willemsen G, Middeldorp CM, Merckelbach HL, Boomsma DI. Heritability of self-reported phobic fear. Behav. Genet. 38(1), 24-33 (2008).
41. Andrews G, Stewart G, Morris-Yates A, Holt P, Henderson S. Evidence for a general neurotic syndrome. Br. J. Psychiatry 157, 6-12 (1990).
42. Merikangas KR, Avenevoli S, Dierker L, Grillon C. Vulnerability factors among children at risk for anxiety disorders. Biol. Psychiatry 46(11), 1523-1535 (1999).
43. Hudson JL, Rapee RM. The origins of social phobia. Behav. Modif. 24(1), 102-129 (2000).
44. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia. Review of a neglected anxiety disorder. Arch. Gen. Psychiatry 42(7), 729-736 (1985).
45. Heimberg RG, Stein MB, Hiripi E, Kessler RC. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades. Eur. Psychiatry 15(1), 29-37 (2000).
46. Wakefield JC, Horwitz AV, Schmitz MF. Are we overpathologizing the socially anxious? Social phobia from a harmful dysfunction perspective. Can. J. Psychiatry. 50(6), 317-319 (2005).
47. Regier DA, Myers JK, Kramer M et al. The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch. Gen. Psychiatry 41(10), 934-941 (1984).
48. Furmark T, Tillfors M, Everz P, Marteinsdottir I, Gefvert O, Fredrikson M. Social phobia in the general population: prevalence and sociodemographic profile. Soc. Psychiatry Psychiatr. Epidemiol. 34(8), 416-424 (1999).
49. Walker JR, Stein MB. Epidemiology. In: Social Phobia: Clinical and Research Perspectives. Stein MB (Ed.). American Psychiatric Press, DC, USA, 43-75 (1995).
50. Campbell-Sills L, Stein MB. Justifying the diagnostic status of social phobia: a reply to Wakefield, Horwitz, and Schmitz. Can. J. Psychiatry. 50(6), 320-323; discussion 324 (2005).
51. Zimmerman M, Chelminski I. Clinician recognition of anxiety disorders in depressed outpatients. J. Psychiatr. Res. 37(4), 325-333 (2003).
52. Weiller E, Bisserbe JC, Boyer P, Lepine JP, Lecrubier Y. Social phobia in general health care: an unrecognised undertreated disabling disorder. Br. J. Psychiatry 168(2), 169-174 (1996).
53. Pollard CA, Henderson JG. Four types of social phobia in a community sample. J. Nerv. Ment. Dis. 176(7), 440-445 (1988).
54. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am. J. Psychiatry 151(3), 408-412 (1994).
55. Stein MB, Walker JR, Forde DR. Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification. Arch. Gen. Psychiatry 53(2), 169-174 (1996).
56. Caraveo-Anduaga JJ, Colmenares E. Prevalencia de los trastornos de ansiedad fobica en la poblacion adulta de la ciudad de Mexico. Salud Mental 23, 10-19 (2000).
57. Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. Br. J. Psychiatry 178, 145-153 (2001).
58. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys estimates. Arch. Gen. Psychiatry 59(2), 115-123 (2002).
59. Beidel DC, Turner SM. The natural course of shyness and related syndromes. In: Extreme Fear, Shyness, and Social Phobia: Origins, Biological Mechanisms, and Clinical Outcomes. Schmidt LA, Schulkin JS (Eds). Oxford University Press, NY, USA, 203-223 (1999).
60. Turner SM, Beidel DC. Social phobia: clinical syndrome, diagnosis, and comorbidity. Clin. Psych. Review 9, 3-18 (1989).
61. Heiser NA, Turner SM, Beidel DC. Shyness: relationship to social phobia and other psychiatric disorders. Behav. Res. Ther. 41(2), 209-221 (2003).
62. Filho AS, Hetem LA, Ferrari MC et al. Social anxiety disorder: what are we losing with the current diagnostic criteria? Acta Psychiatr. Scand. 121(3), 216-226 (2010).
63. Kollman DM, Brown TA, Liverant GI, Hofmann SG. A taxometric investigation of the latent structure of social anxiety disorder in outpatients with anxiety and mood disorders. Depress. Anxiety 23(4), 190-199 (2006).
64. Ruscio AM. The latent structure of social anxiety disorder: consequences of shifting to a dimensional diagnosis. J. Abnorm. Psychol. 119(4), 662-671 (2010).
65. Bgels SM, Alden L, Beidel DC et al. Social anxiety disorder: questions and answers for the DSM-V. Depress. Anxiety 27(2), 168-189 (2010).
66. Chambless DL, Fydrich T, Rodebaugh TL. Generalized social phobia and avoidant personality disorder: meaningful distinction or useless duplication? Depress. Anxiety 25(1), 8-19 (2008).
67. Tillfors M, Furmark T, Ekselius L, Fredrikson M. Social phobia and avoidant personality disorder as related to parental history of social anxiety: a general population study. Behav. Res. Ther. 39(3), 289-298 (2001).
68. Hummelen B, Wilberg T, Pedersen G, Karterud S. The relationship between avoidant personality disorder and social phobia. Compr. Psychiatry 48(4), 348-356 (2007).
69. Asarnow RF, Nuechterlein KH, Fogelson D et al. Schizophrenia and schizophreniaspectrum personality disorders in the first-degree relatives of children with schizophrenia: the UCLA family study. Arch. Gen. Psychiatry 58(6), 581-588 (2001).
70. Dalrymple KL, Zimmerman M. Treatment-seeking for social anxiety disorder in a general outpatient psychiatry setting. Psychiatry Res. 187(3), 375-381 (2011).
71. Dalrymple KL, Zimmerman M. Differences in clinical presentation between depressed outpatients wanting versus not wanting treatment for comorbid social anxiety disorder. J. Nerv. Ment. Dis. 196(8), 639-642 (2008).
72. Coles ME, Coleman SL. Barriers to treatment seeking for anxiety disorders: initial data on the role of mental health literacy. Depress. Anxiety 27(1), 63-71 (2010).
73. Olfson M, Guardino M, Struening E, Schneier FR, Hellman F, Klein DF. Barriers to the treatment of social anxiety. Am. J. Psychiatry 157(4), 521-527 (2000).
74. Rapee RM. Descriptive psychopathology of social phobia. In: Social Phobia: Diagnosis, Assessment, and Treatment. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR (Eds). Guilford Press, NY, USA, 41-66 (1995).
75. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry 49(4), 282-288 (1992).
76. Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. Free Press, NY, USA (1991).
77. Messias E, Eaton W, Nestadt G, Bienvenu OJ, Samuels J. Psychiatrists ascertained treatment needs for mental disorders in a population-based sample. Psychiatr. Serv. 58(3), 373-377 (2007).
78. Wagner R, Silove D, Marnane C, Rouen D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J. Anxiety Disord. 20(3), 363-371 (2006).
79. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J. Abnorm. Psychol. 110(4), 585-599 (2001).
80. Dalrymple KL, Zimmerman M. Does comorbid social anxiety disorder impact the clinical presentation of principal major depressive disorder? J. Affect. Disord. 100(1-3), 241-247 (2007).
81. Stein MB, Fuetsch M, Mller N, Hfler M, Lieb R, Wittchen HU. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch. Gen. Psychiatry 58(3), 251-256 (2001).
82. Nelson EC, Grant JD, Bucholz KK et al. Social phobia in a population-based female adolescent twin sample: co-morbidity and associated suicide-related symptoms. Psychol. Med. 30(4), 797-804 (2000).
83. Angst J, Gamma A, Rssler W, Ajdacic V, Klein DN. Long-term depression versus episodic major depression: results from the prospective Zurich study of a community sample. J. Affect. Disord. 115(1-2), 112-121 (2009).
84. Watanabe N, Furukawa TA, Chen J et al. Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study. BMC Psychiatry 10, 81 (2010).
85. Rodebaugh TL, Holaway RM, Heimberg RG. The treatment of social anxiety disorder. Clin. Psychol. Rev. 24(7), 883-908 (2004).
86. Clark DM, Ehlers A, McManus F et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J. Consult. Clin. Psychol. 71(6), 1058-1067 (2003).
87. Andersson G. Using the Internet to provide cognitive behaviour therapy. Behav. Res. Ther. 47(3), 175-180 (2009).
88. Davidson JRT. Pharmacotherapy of social phobia. Acta Psychiatr. Scand. 108(Suppl. 417), 65-71 (2003).
89. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int. Clin. Psychopharmacol. 15(Suppl. 2), S15-S23 (2000).
90. Blanco C, Schneier FR, Schmidt A et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress. Anxiety 18(1), 29-40 (2003).
91. Heimberg RG, Liebowitz MR, Hope DA et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry 55(12), 1133-1141 (1998).
92. Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin. Psychol. Sci. Pract. 4, 291-306 (1997).
93. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J. Clin. Psychopharmacol. 21(3), 311-324 (2001).
94. Davidson JR, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch. Gen. Psychiatry 61(10), 1005-1013 (2004).
95. Otto MW, Pollack MH, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitivebehavioral group therapy for the treatment of social phobia. J. Anxiety Disord. 14(4), 345-358 (2000).
96. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch. Gen. Psychiatry 59(12), 1111-1118 (2002).
97. Stein MB, Chartier MJ, Hazen AL et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16(3), 218-222 (1996).
98. Walker JR, Van Ameringen MA, Swinson R et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J. Clin. Psychopharmacol. 20(6), 636-644 (2000).
99. Liebowitz MR, Heimberg RG, Schneier FR et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress. Anxiety 10(3), 89-98 (1999).
100. Blomhoff S, Haug TT, Hellstrm K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br. J. Psychiatry 179, 23-30 (2001).
101. Blanco C, Heimberg RG, Schneier FR et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch. Gen. Psychiatry 67(3), 286-295 (2010).
102. Fava GA, Grandi S, Rafanelli C, Ruini C, Conti S, Belluardo P. Long-term outcome of social phobia treated by exposure. Psychol. Med. 31(5), 899-905 (2001).
103. Haug TT, Blomhoff S, Hellstrm K et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br. J. Psychiatry 182, 312-318 (2003).
104. Mowrer OH. On the dual nature of learning: a re-interpretation of conditioning and problem-solving. Harvard Educ. Rev. 17, 102-148 (1947).
105. Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. Guilford Press, NY, USA (1988).
106. Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A. Optimizing inhibitory learning during exposure therapy. Behav. Res. Ther. 46(1), 5-27 (2008).
107. Otto MW, Smits JA, Reese HE. Cognitivebehavioral therapy for the treatment of anxiety disorders. J. Clin. Psychiatry 65(Suppl. 5), 34-41 (2004).
108. Sutherland SM, Tupler LA, Colket JT, Davidson JR. A 2-year follow-up of social phobia. Status after a brief medication trial. J. Nerv. Ment. Dis. 184(12), 731-738 (1996).
109. Davidson JR, Potts N, Richichi E et al. Treatment of social phobia with clonazepam and placebo. J. Clin. Psychopharmacol. 13(6), 423-428 (1993).
110. Versiani M, Nardi AE, Figueira I et al. Double-blind placebo controlled trial with bromazepam in social phobia. J. Bras. Psiq. 46, 167-171 (1997).
111. Fontaine R, Chouinard G, Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am. J. Psychiatry 141(7), 848-852 (1984).
112. Connor KM, Davidson JR, Potts NL et al. Discontinuation of clonazepam in the treatment of social phobia. J. Clin. Psychopharmacol. 18(5), 373-378 (1998).
113. Vikander B, Koechling UM, Borg S, Tnne U, Hiltunen AJ. Benzodiazepine tapering: a prospective study. Nord. J. Psychiatry 64(4), 273-282 (2010).
114. Lader M. Benzodiazepines revisited -will we ever learn? Addiction 106(12), 2086-2109 (2011).
115. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 23(1), 19-34 (2009).
116. Canadian Psychiatric Association. Clinical practice guidelines for the management of anxiety disorders: 5. Social anxiety disorder. Can. J. Psychiatry 51, 35S-42S (2006).
117. Levitan MN, Chagas MH, Crippa JA et al.; Brazilian Medical Association. [Guidelines of the Brazilian Medical Association for the treatment of social anxiety disorder]. Rev. Bras. Psiquiatr. 33(3), 292-302 (2011).
118. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J. Clin. Psychiatry 65(2), 244-248 (2004).
119. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 67(1), 26-36 (2010).
120. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HC. Deaths: Preliminary data for 2009. U.S. Department of Health and Human Services, Center for Disease Control and Prevention (2011).
121. National Institute of Drug Abuse. Research Report: Prescription Drugs: Abuse and Addiction. National Institutes of Health, MA, USA (2005).
122. Lagnaoui R, Depont F, Fourrier A et al. Patterns and correlates of benzodiazepine use in the French general population. Eur. J. Clin. Pharmacol. 60(7), 523-529 (2004).
123. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress. Anxiety 22(2), 59-67 (2005).
124. Versiani M, Amrein R, Montgomery SA. Social phobia: long-term treatment outcome and prediction of response -a moclobemide study. Int. Clin. Psychopharmacol. 12(5), 239-254 (1997).
125. Davidson JR. Pharmacotherapy of social anxiety disorder. J. Clin. Psychiatry 59(Suppl. 17), 47-53 (1998).
126. Rosser S, Erskine A, Crino R. Pre-existing antidepressants and the outcome of group cognitive behaviour therapy for social phobia. Aust. NZ J. Psychiatry 38(4), 233-239 (2004).
127. Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron 36(4), 567-584 (2002).
128. Hofmann SG, Meuret AE, Smits JA et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 63(3), 298-304 (2006).
129. Guastella AJ, Richardson R, Lovibond PF et al. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 63(6), 544-549 (2008).
130. Nations KR, Smits JA, Tolin DF et al. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 73(5), 647-653 (2012).
131. Siegmund A, Golfels F, Finck C et al. d-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J. Psychiatr. Res. 45(8), 1042-1047 (2011).
132. Davis M. NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin. Neurosci. 13(4), 463-474 (2011).
133. Karpova NN, Pickenhagen A, Lindholm J et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334(6063), 1731-1734 (2011).
134. Bourin M, Fiocco AJ, Clenet F. How valuable are animal models in defining antidepressant activity? Hum. Psychopharmacol. 16(1), 9-21 (2001).
135. Steimer T. Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues Clin. Neurosci. 13(4), 495-506 (2011).
136. Buckner JD, Heimberg RG, Schmidt NB. Social anxiety and marijuana-related problems: the role of social avoidance. Addict. Behav. 36(1-2), 129-132 (2011).
137. Abramowitz JS, Moore EL, Braddock AE, Harrington DL. Self-help cognitivebehavioral therapy with minimal therapist contact for social phobia: a controlled trial. J. Behav. Ther. Exp. Psychiatry 40(1), 98-105 (2009).
138. Tillfors M, Carlbring P, Furmark T et al. Treating university students with social phobia and public speaking fears: Internet delivered self-help with or without live group exposure sessions. Depress. Anxiety 25(8), 708-717 (2008).
139. McCrone P, Marks IM, Mataix-Cols D, Kenwright M, McDonough M. Computeraided self-exposure therapy for phobia/ panic disorder: a pilot economic evaluation. Cogn. Behav. Ther. 38(2), 91-99 (2009).
140. Ledley DR, Huppert JD, Foa EB, Davidson JR, Keefe FJ, Potts NL. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depress. Anxiety 22(4), 161-167 (2005).
141. Marom S, Gilboa-Schechtman E, Aderka IM, Weizman A, Hermesh H. Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy. Depress. Anxiety 26(3), 289-300 (2009).
142. Erwin BA, Heimberg RG, Juster H, Mindlin M. Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav. Res. Ther. 40(1), 19-35 (2002).
143. Joorman J, Kosfelder J, Schulte D. The impact of comorbidity of depression on the course of anxiety treatments. Cog. Ther. Res. 29, 569-591 (2005).
144. Schneier FR, Blanco C, Campeas R et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety 17(4), 191-196 (2003).
145. Mennin DS, Heimberg RG, Jack MS. Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. J. Anxiety Disord. 14(4), 325-343 (2000).
146. van Velzen CJ, Emmelkamp PM, Scholing A. The impact of personality disorders on behavioral treatment outcome for social phobia. Behav. Res. Ther. 35(10), 889-900 (1997).
147. Bricker JB, Russo J, Stein MB et al. Does occasional cannabis use impact anxiety and depression treatment outcomes? Results from a randomized effectiveness trial. Depress. Anxiety 24(6), 392-398 (2007).
148. Brown TA, Di Nardo P, Barlow DH. Anxiety Disorders Interview Schedule for DSM-IV. The Psychological Corporation, TX, USA (1994).
149. de Lima Osório F, Crippa JA, Loureiro SR. A study of the discriminative validity of a screening tool (MINI-SPIN) for social anxiety disorder applied to Brazilian university students. Eur. Psychiatry 22(4), 239-243 (2007).
150. Wilamowska ZA, Thompson-Hollands J, Fairholme CP, Ellard KK, Farchione TJ, Barlow DH. Conceptual background, development, and preliminary data from the unified protocol for transdiagnostic treatment of emotional disorders. Depress. Anxiety 27(10), 882-890 (2010).
151. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change. Guilford Press, NY, USA (1999).
152. Pratt LA, Brody DJ, Gu Q. Antidepressant Use in Persons Aged 12 and Over: United States, 2005-2008. National Center for Health Statistics, MD, USA (2011).